Chikungunya fever (CF) is caused by an arbovirus which is transmitted through Aedes mosquitoes. It is a single stranded RNA virus belonging to the Alphavirus genus of the Togaviridae, the characteristic feature of the family of this virus is they are mostly transmitted by arthropods. In 1952-1953 Tanzania had the outbreak for the first time and samples of both man and mosquitoes contained the virus. The virus is heat labile in nature and is found to be sensitive to temperatures above 580 Celsius. The virus uses Aedes aegypti mosquitoes as the common vector for transmitting the infection in urban areas and Aedes albopictus transmits in the rural areas.
Considering the epidemiology of the disease, it is mostly observed in the South-East Asia region and a human-mosquito-human transmission cycle is observed which is different from that of the sylvatic transmission cycle described on the African continent. A high vector density is observed during the post monsoon season which increases the transmission. Chikungunya fever epidemics display cyclical and seasonal trends. During the post monsoon period human beings serve as the Chikungunya virus reservoir, whereas, during inter-epidemic periods, vertebrates like monkeys, rodents, birds, and others get affected.
The clinical features observed in the chikungunya virus are fever (92%) usually associated with arthralgia (87%), backache (67%) and headache (62%). Low or high grade fever reaching 39 to 40 Degrees Celsius, with shaking chills and rigors can be observed that lasts for 24 to 48 hours and the use of antipyretics can subside it. Patients may also have arthralgia without fever where the joint pain worsens in the morning and can be relieved by mild exercise. It may get remited for 2-3 days and then reappear in a saddle back pattern. Migratory polyarthritis with effusions can also be observed in 70% cases, but resolves in the majority. Joints like ankles, wrists and small joints of the hand are worst affected. The classical bending phenomenon may occur due to the lower limb and back involvement, this makes the patient stoop down and bend forward.
The three phases of chikungunya infection are acute phase (less than 3 weeks), sub-acute phase (> 3 weeks to 3 months), chronic phase (> 3 months) and the clinical presentation can be mild, moderate or severe depending upon the symptoms. Other clinical features include mucocutaneous manifestation where transient maculopapular rash is observed in 50 % patients. Also angiomatous lesions, purpuras, stomatitis, oral ulcers, nasal blotchy erythema are observed in the patients. Apart from this, exfoliative dermatitis, epidermolysis bullosa and ocular manifestation can be observed. Ocular manifestations including photophobia and retro-orbital pain may also be seen. Neuroretinitis and uveitis in one or both eyes are also observed in patients.
1.
Data indicate 1 in 3 US adults unaware of connection between HPV and cancers
2.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
3.
New imaging probe helps track prostate cancer and possibly treat it before resistance develops
4.
A novel blood test may enable the early identification of common, fatal cancers.
5.
Children living near oil and gas wells face higher risk of rare leukemia, studies show
1.
What You Need to Know About the Early Warning Signs of Colon Cancer
2.
Uncovering the Hidden Picture: Using Ultrasound to Diagnose Breast Cancer
3.
Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells
4.
Unlocking the Potential of Reticulocytes: The Key to Enhanced Blood Production
5.
Unlocking the Potential of Polatuzumab for Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Navigating the Complexities of Ph Negative ALL - Part XII
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation